Leerink Partnrs Has Strong Estimate for TVTX FY2026 Earnings

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Analysts at Leerink Partnrs boosted their FY2026 EPS estimates for Travere Therapeutics in a report released on Tuesday, February 11th. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings of $0.63 per share for the year, up from their previous estimate of $0.52. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($3.90) per share.

TVTX has been the topic of several other research reports. Evercore ISI lifted their price target on shares of Travere Therapeutics from $33.00 to $45.00 and gave the stock an “outperform” rating in a research report on Wednesday. Cantor Fitzgerald started coverage on shares of Travere Therapeutics in a research note on Friday, January 10th. They issued an “overweight” rating for the company. Barclays raised their price objective on shares of Travere Therapeutics from $18.00 to $20.00 and gave the stock an “overweight” rating in a research note on Friday, November 1st. Piper Sandler raised their price objective on shares of Travere Therapeutics from $12.00 to $22.00 and gave the stock a “neutral” rating in a research note on Thursday, November 14th. Finally, HC Wainwright raised their price objective on shares of Travere Therapeutics from $18.00 to $22.00 and gave the stock a “buy” rating in a research note on Wednesday, January 15th. One investment analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $27.77.

Travere Therapeutics Trading Down 3.4 %

Travere Therapeutics stock opened at $22.91 on Thursday. The company has a debt-to-equity ratio of 24.96, a quick ratio of 1.68 and a current ratio of 1.71. The firm has a market cap of $1.79 billion, a price-to-earnings ratio of -5.04 and a beta of 0.72. Travere Therapeutics has a 1 year low of $5.12 and a 1 year high of $25.29. The firm’s 50 day moving average price is $19.22 and its two-hundred day moving average price is $16.10.

Institutional Investors Weigh In On Travere Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. RA Capital Management L.P. acquired a new stake in shares of Travere Therapeutics in the 4th quarter valued at $20,033,000. Freestone Grove Partners LP bought a new position in Travere Therapeutics in the 4th quarter worth $445,000. AQR Capital Management LLC raised its holdings in Travere Therapeutics by 117.8% in the 4th quarter. AQR Capital Management LLC now owns 424,024 shares of the company’s stock worth $7,386,000 after acquiring an additional 229,361 shares during the period. Northern Trust Corp raised its holdings in Travere Therapeutics by 11.3% in the 4th quarter. Northern Trust Corp now owns 754,395 shares of the company’s stock worth $13,142,000 after acquiring an additional 76,358 shares during the period. Finally, Tudor Investment Corp ET AL raised its holdings in Travere Therapeutics by 13.3% in the 4th quarter. Tudor Investment Corp ET AL now owns 43,213 shares of the company’s stock worth $753,000 after acquiring an additional 5,069 shares during the period.

Insider Buying and Selling at Travere Therapeutics

In related news, CAO Sandra Calvin sold 12,090 shares of Travere Therapeutics stock in a transaction on Monday, November 25th. The shares were sold at an average price of $18.30, for a total value of $221,247.00. Following the completion of the sale, the chief accounting officer now owns 54,927 shares of the company’s stock, valued at approximately $1,005,164.10. The trade was a 18.04 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP William E. Rote sold 2,437 shares of Travere Therapeutics stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $19.46, for a total transaction of $47,424.02. Following the completion of the sale, the senior vice president now directly owns 83,170 shares of the company’s stock, valued at approximately $1,618,488.20. The trade was a 2.85 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 218,425 shares of company stock valued at $4,674,259 in the last quarter. Company insiders own 3.75% of the company’s stock.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.